Thrombogenics Awarded €1.1 Million IWT Research Grant

ThromboGenics NV has announced that it has been awarded a €1.1 million research grant from the Flemish agency for Innovation by Science and Technology (IWT).

The grant will be used by Thrombogenics to fund the on-going research to further elucidate the pharmacological effects ocriplasmin is exerting in the back of the eye following intravitreal (IVT) injection.

Dr Patrik De Haes, CEO of ThromboGenics comments: “The award of this grant from IWT supports our commitment to gain further insight into JETREA®s action in the vitreo-retinal interface. In conjunction with a growing body of real world and clinical trial data, we hope that the continual efforts at the preclinical research level will contribute to an improved awareness and acceptance of JETREA® by physicians as a first in class pharmaceutical treatment for symptomatic VMA.”